- Home
- MGY vs NAMS Comparison
MGY vs NAMS Comparison
Compare MGY & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGY | NAMS |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGY | NAMS |
|---|---|---|
| Price | $26.71 | $34.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $26.23 | ★ $47.38 |
| AVG Volume (30 Days) | ★ 3.5M | 584.0K |
| Earning Date | 02-05-2026 | 03-02-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $1,311,845,000.00 | $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.26 | $11.19 |
| P/E Ratio | $15.49 | ★ N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $19.09 | $14.06 |
| 52 Week High | $27.47 | $42.00 |
Technical Indicators
Market Signals| Indicator | MGY | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 58.24 |
| Support Level | $25.53 | $33.14 |
| Resistance Level | $27.47 | $35.61 |
| Average True Range (ATR) | 0.80 | 1.40 |
| MACD | 0.01 | 0.43 |
| Stochastic Oscillator | 57.10 | 94.24 |
Price Performance
Historical ComparisonAbout MGY Magnolia Oil & Gas Corporation
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.